Recursion Pharmaceuticals (RXRX) Jefferies 2024 Global Healthcare Conference summary

Technology and data strategy

• Utilizes high-throughput automated wet labs, generating up to 2.2 million experiments weekly and aggregating over 50 PB of biological, chemical, and clinical data.

• Applies advanced computational resources, including supercomputers and large language models, to map complex biological relationships and drive drug discovery.

• Integrates proprietary and public data to identify novel biological relationships, leveraging data arbitrage for unique insights.

• Employs a modular operating system, enabling flexible, scalable workflows across drug discovery and development.

• Continuously adds new modules and AI-driven tools, such as the LOWE workflow engine, to enhance automation and discovery.

Pipeline and clinical development

• Internal pipeline focuses on precision oncology and rare diseases, with seven programs advancing toward key milestones within 18 months.

• Notable programs include phase II trials in cerebral cavernous malformation, neurofibromatosis type 2, familial adenomatous polyposis, and advanced AXIN1 APC mutant cancers.

• Additional programs target C. difficile infection, HR-proficient cancers (RBM39), and fibrotic disease (Target Epsilon), with IND submissions and trial initiations expected soon.

• Demonstrates reduced time and cost to reach IND and validated leads compared to industry averages.

• Emphasizes novelty by prioritizing targets and relationships not well known in scientific literature.

Partnerships and collaborations

• Strategic partnerships with Roche Genentech (neuroscience, GI oncology), Bayer (undruggable oncology), and NVIDIA (high-performance computing, BioNeMo platform).

• Collaborations with Tempus and Helix provide access to multimodal patient data, enhancing clinical and genetic insights.

• Partnership with Enamine enabled large-scale chemoproteomic calculations across 36 billion compounds.

• Data strategy includes licensing subsets of proprietary data and tools to biopharma customers.

• Ongoing discussions for additional partnerships in large, tractable biological and technology areas.